346 related articles for article (PubMed ID: 38386282)
1. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
[TBL] [Abstract][Full Text] [Related]
2. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.
Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G
Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.
Shae D; Baljon JJ; Wehbe M; Christov PP; Becker KW; Kumar A; Suryadevara N; Carson CS; Palmer CR; Knight FC; Joyce S; Wilson JT
ACS Nano; 2020 Aug; 14(8):9904-9916. PubMed ID: 32701257
[TBL] [Abstract][Full Text] [Related]
4. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
5. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
6. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
7. A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA.
Carson CS; Becker KW; Garland KM; Pagendarm HM; Stone PT; Arora K; Wang-Bishop L; Baljon JJ; Cruz LD; Joyce S; Wilson JT
J Control Release; 2022 May; 345():354-370. PubMed ID: 35301055
[TBL] [Abstract][Full Text] [Related]
8. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
9. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
10. Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy.
Su T; Liu X; Lin S; Cheng F; Zhu G
Bioact Mater; 2023 Aug; 26():169-180. PubMed ID: 36883121
[TBL] [Abstract][Full Text] [Related]
11. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ
Front Immunol; 2022; 13():936129. PubMed ID: 36059502
[TBL] [Abstract][Full Text] [Related]
12. Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines.
Qiu F; Becker KW; Knight FC; Baljon JJ; Sevimli S; Shae D; Gilchuk P; Joyce S; Wilson JT
Biomaterials; 2018 Nov; 182():82-91. PubMed ID: 30107272
[TBL] [Abstract][Full Text] [Related]
13. Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles.
Yan H; Lin G; Liu Z; Gu F; Zhang Y
Acta Biomater; 2023 Apr; 161():213-225. PubMed ID: 36858163
[TBL] [Abstract][Full Text] [Related]
14. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy.
Liu M; Feng Y; Lu Y; Huang R; Zhang Y; Zhao Y; Mo R
Sci Adv; 2024 Mar; 10(11):eadk2444. PubMed ID: 38478602
[TBL] [Abstract][Full Text] [Related]
15. Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1.
Traini G; Ruiz-de-Angulo A; Blanco-Canosa JB; Zamacola Bascarán K; Molinaro A; Silipo A; Escors D; Mareque-Rivas JC
Small; 2019 Jan; 15(4):e1803993. PubMed ID: 30569516
[TBL] [Abstract][Full Text] [Related]
16. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
Lin Z; Jiang C; Wang P; Chen Q; Wang B; Fu X; Liang Y; Zhang D; Zeng Y; Liu X
Theranostics; 2023; 13(12):4166-4181. PubMed ID: 37554274
[No Abstract] [Full Text] [Related]
18. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine.
Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L
Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338
[TBL] [Abstract][Full Text] [Related]
19. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
20. Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8
Darling R; Senapati S; Christiansen J; Liu L; Ramer-Tait AE; Narasimhan B; Wannemuehler M
Int J Nanomedicine; 2020; 15():6579-6592. PubMed ID: 32982219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
